A novel traditional Chinese medicine ameliorates fatigue-induced cardiac hypertrophy and dysfunction via regulation of energy metabolism.

Abstract

Prolonged exercise and exercise training can adversely affect cardiac function in some individuals. QiShenYiQi Pills (QSYQ), which are a compound Chinese medicine, have been previously shown to improve pressure overload-induced cardiac hypertrophy. We hypothesized that QSYQ can ameliorate as well the fatigue-induced cardiac hypertrophy. This study was to test this hypothesis and underlying mechanism with a focus on its role in energy regulation. Male Sprague-Dawley rats were used to establish exercise adaptation and fatigue model on a motorized rodent treadmill. Echocardiographic analysis and heart function test were performed to assess heart systolic function. Food-intake weight/body weight and heart weight/body weight were assessed, and hematoxylin and eosin staining and immunofluorescence staining of myocardium sections were performed. ATP synthase expression and activity and ATP, ADP, and AMP levels were assessed using Western blot and ELISA. Expression of proteins related to energy metabolism and IGF-1R signaling was determined using Western blot. QSYQ attenuated the food-intake weight/body weight decrease, improved myocardial structure and heart function, and restored the expression and distribution of myocardial connexin 43 after fatigue, concomitant with an increased ATP production and a restoration of metabolism-related protein expression. QSYQ upgraded the expression of IGF-1R, P-AMPK/AMPK, peroxisome proliferator-activated receptor-γ coactivator-1α, nuclear respiratory factor-1, P-phosphatidylinositol 3-kinase (PI3K)/PI3K, and P-Akt/Akt thereby attenuated the dysregulation of IGF-1R signaling after fatigue. QSYQ relieved fatigue-induced cardiac hypertrophy and enhanced heart function, which is correlated with its potential to improve energy metabolism by regulating IGF-1R signaling. NEW & NOTEWORTHY Prolonged exercise may impact some people leading to pathological cardiac hypertrophy. This study using an animal model of fatigue-induced cardiac hypertrophy provides evidence showing the potential of QiShenYiQi Pills, a novel traditional Chinese medicine, to prevent the cardiac adaptive hypertrophy from development to pathological hypertrophy and demonstrates that this effect is correlated with its capacity for regulating energy metabolism through interacting with insulin-like growth factor-1 receptor.

• Authors: Rong Huang, Yuan-Chen Cui, Xiao-Hong Wei, Chun-Shui Pan, Quan Li, Shu-Ya He, Jing-Yu Fan, Jing-Yan Han
• Journal: American journal of physiology. Heart and circulatory physiology (Am J Physiol Heart Circ Physiol) Vol. 316 Issue 6 Pg. H1378-H1388 (06 01 2019) ISSN: 1522-1539 [Electronic] United States
• PMID: 30951366 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cardiovascular Agents
• Drugs, Chinese Herbal
• qishen yiqi
• Adenosine Triphosphate
• Receptor, IGF Type 1
• Proto-Oncogene Proteins c-akt

Topics

• Adenosine Triphosphate (metabolism)
• Animals
• Cardiovascular Agents (pharmacology)
• Cell Line
• Disease Models, Animal
• Drugs, Chinese Herbal (pharmacology)
• Energy Metabolism (drug effects)
• Fatigue (complications, drug therapy, metabolism, physiopathology)
• Hypertrophy, Left Ventricular (drug therapy, etiology, metabolism, physiopathology)
• Male
• Myocytes, Cardiac (drug effects, metabolism)
• Phosphorylation
• Proto-Oncogene Proteins c-akt (metabolism)
• Rats, Sprague-Dawley
• Receptor, IGF Type 1 (metabolism)
• Signal Transduction
• Ventricular Function, Left (drug effects)
• Ventricular Remodeling (drug effects)